Table 2 Clinical-pathological prognostic features of disease
From: Detection methods predict differences in biology and survival in breast cancer patients
Incident (n = 65) vs. Symptomatic (n = 130) | P value | OR adjusted by tumor size | |
|---|---|---|---|
Mean age | 59.7 ± 0.68 vs. 56.3 ± 1.14 | p < 0.05 | 1.04 (1.01-1.08) |
Mean size (cm) | 1.27 ± 0.17 vs. 2.68 ± 0.15 | p < 0.001 | -- |
Lymph node positive | 21.5% vs. 48.9% | p < 0.001 | 0.78 (0.34-1.76) |
Poorly differentiated tumors | 32.8 vs. 39.7% | N.S. | 0.56 (0.27-1.17) |
ER positive | 89.1% vs. 57.4% | p < 0.001 | 4.23 (1.61-11.12) |
PR positive | 78.2 vs. 36.4% | p < 0.001 | 4.60 (2.11-10.03) |
In situ carcinomas | 11% vs. 1.5% | p < 0.001 | 2.44 (0.42-13.87) |
Apoptosis | 66.7% vs. 38.5% | p < 0.05 | 5.06 (1.71-14.94) |
Bcl-2 | 81.3% vs. 62.7% | p < 0.05 | 1.39 (0.89-2.19) |
c-erb-B2 | 26.3% vs. 23% | N.S. | 0.86 (0.21-3.53) |
Ki67 | 63% vs. 52.5% | N.S. | 1.96 (0.93-4.09) |
Delay Diagnosis- treatment (>30 days) | 35.4% vs. 57% | p < 0.05 | 0.47 (0.23-0.95) |